Clinical implications of benign multiple sclerosis: A 20‐year population‐based follow‐up study

In 2001, we followed up all patients from the 1991 Olmsted County Multiple Sclerosis (MS) prevalence cohort. We found that the longer the duration of MS and the lower the disability, the more likely a patient is to remain stable and not progress. This is particularly powerful for patients with benign MS with Expanded Disability Status Scale score of 2 or lower for 10 years or longer who have a greater than 90% chance of remaining stable. This is important because these patients represent 17% of the entire prevalence cohort. These data should assist in the shared therapeutic decision‐making process of whether to start immunomodulatory medications. Ann Neurol 2004;56:303–306

[1]  L. Kurland,et al.  Impairment, disability, and handicap in multiple sclerosis , 1994, Neurology.

[2]  Lublin Fd,et al.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. , 1996 .

[3]  W. Firnhaber,et al.  PROGNOSTIC CRITERIA IN MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.

[4]  D. Mcalpine.  The benign form of multiple sclerosis. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. , 1961, Brain : a journal of neurology.

[5]  G V McDonnell,et al.  Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors , 1999, Journal of neurology, neurosurgery, and psychiatry.

[6]  N. Møller,et al.  Growth Hormone and Glucose Homeostasis , 2004, Hormone Research in Paediatrics.

[7]  G. Beebe,et al.  Studies on the natural history of multiple sclerosis--8. Early prognostic features of the later course of the illness. , 1977, Journal of chronic diseases.

[8]  S. Weigand,et al.  Change in MS-related disability in a population-based cohort , 2004, Neurology.

[9]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[10]  D. Mcalpine.  The Benign form of Multiple Sclerosis: Results of a Long-term Study , 1964, British medical journal.

[11]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.

[12]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[13]  S. Poser,et al.  Clinical data and the identification of special forms of multiple sclerosis in 1271 cases studied with a standardized documentation system , 1979, Journal of the Neurological Sciences.

[14]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[15]  A. Rascol,et al.  [The course of multiple sclerosis. Study of 203 cases followed up for more than 10 years]. , 1971, Revue neurologique.

[16]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[17]  L. Munari,et al.  Interferons in relapsing remitting multiple sclerosis : a systematic review , 2022 .

[18]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[19]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. , 1991, Brain : a journal of neurology.

[20]  O. Vuia.  THE BENIGN FORM OF MULTIPLE SCLEROSIS , 1977 .

[21]  R. Slater.  Criteria and uses of the Minimal Record of Disability in multiple sclerosis , 1984, Acta neurologica Scandinavica. Supplementum.